Long-Acting Beta Agonist Asthma Pharmacogenetic Loci Identified in Two Multi-Racial Asthma Clinical Trials
V. Ortega (Winston-Salem, NC, United States of America), M. Daya (Denver, CO, United States of America), E. Ampleford (Winston-Salem, NC, United States of America), G. Hawkins (Winston-Salem, NC, United States of America), W. Moore (Winston-Salem, NC, United States of America), S. Peters (Winston-Salem, NC, United States of America), K. Barnes (Denver, CO, United States of America), E. Bleecker (Tucson, AZ, United States of America), D. Meyers (Tucson, AZ, United States of America)
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Session: Asthma clinical trials and real-life studies
Session type: E-poster
Number: 886
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Ortega (Winston-Salem, NC, United States of America), M. Daya (Denver, CO, United States of America), E. Ampleford (Winston-Salem, NC, United States of America), G. Hawkins (Winston-Salem, NC, United States of America), W. Moore (Winston-Salem, NC, United States of America), S. Peters (Winston-Salem, NC, United States of America), K. Barnes (Denver, CO, United States of America), E. Bleecker (Tucson, AZ, United States of America), D. Meyers (Tucson, AZ, United States of America). Long-Acting Beta Agonist Asthma Pharmacogenetic Loci Identified in Two Multi-Racial Asthma Clinical Trials. 886
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: